Cubist Systematic Strategies LLC Sells 220,662 Shares of Bionano Genomics, Inc. (NASDAQ:BNGO)

Cubist Systematic Strategies LLC lowered its holdings in Bionano Genomics, Inc. (NASDAQ:BNGO) by 80.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 52,510 shares of the company’s stock after selling 220,662 shares during the period. Cubist Systematic Strategies LLC’s holdings in Bionano Genomics were worth $385,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Ground Swell Capital LLC bought a new stake in Bionano Genomics in the 2nd quarter valued at about $88,000. SG Americas Securities LLC bought a new stake in shares of Bionano Genomics during the 2nd quarter worth approximately $106,000. Rhumbline Advisers bought a new stake in shares of Bionano Genomics during the 2nd quarter worth approximately $2,120,000. Mutual Advisors LLC bought a new stake in shares of Bionano Genomics during the 2nd quarter worth approximately $118,000. Finally, Capula Management Ltd lifted its holdings in shares of Bionano Genomics by 139.1% during the 2nd quarter. Capula Management Ltd now owns 25,467 shares of the company’s stock worth $187,000 after acquiring an additional 14,815 shares during the period. 26.73% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ BNGO opened at $4.09 on Thursday. Bionano Genomics, Inc. has a 52-week low of $0.48 and a 52-week high of $15.69. The firm has a 50 day moving average price of $5.19 and a two-hundred day moving average price of $5.86. The stock has a market cap of $1.18 billion, a P/E ratio of -17.04 and a beta of 1.78.

BNGO has been the subject of a number of research analyst reports. Maxim Group initiated coverage on shares of Bionano Genomics in a research report on Friday, November 5th. They set a “buy” rating and a $12.00 price objective for the company. Zacks Investment Research cut shares of Bionano Genomics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $11.56.

About Bionano Genomics

Bionano Genomics, Inc is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics.

Featured Story: Channel Trading

Institutional Ownership by Quarter for Bionano Genomics (NASDAQ:BNGO)

Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.